{
    "nct_id": "NCT01467726",
    "title": "A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects",
    "status": "COMPLETED",
    "last_update_time": "2025-07-03",
    "description_brief": "This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Velusetrag (TD-5108) \u2014 small\u2011molecule 5\u2011HT4 (serotonin) receptor agonist"
    ],
    "placebo": [
        "Matching placebo (per trial design)"
    ],
    "explanation_target": [
        "Reason: The intervention is velusetrag, an orally active small\u2011molecule agonist of the serotonin 5\u2011HT4 receptor; 5\u2011HT4 agonists are pro\u2011kinetic GI agents but have been studied for CNS effects (increase acetylcholine release, modulate APP processing) suggesting potential effects on Alzheimer pathology and cognition. \ue200cite\ue202turn0search5\ue202turn1search1\ue201.",
        "Act: Trial details \u2014 Phase 1, randomized, placebo\u2011controlled, double\u2011blind safety/PK/PD study in healthy elderly subjects (velusetrag vs matching placebo). The sponsor/developer literature describes velusetrag as a selective 5\u2011HT4 receptor agonist developed for GI motility disorders but lists Alzheimer\u2019s disease as a research/indication area in trial registries; preclinical work shows 5\u2011HT4 agonists (including velusetrag) can affect APP processing and cognitive endpoints. \ue200cite\ue202turn0search4\ue202turn0search2\ue202turn1search1\ue201.",
        "Reflect: Classification rationale \u2014 velusetrag is a small molecule (not a biologic) and has preclinical evidence suggesting it can modulate Alzheimer\u2019s\u2011relevant biology (APP/A\u03b2 processing and tau in animal models) as well as symptomatic cognitive effects via cholinergic modulation; therefore it best fits the 'disease\u2011targeted small molecule' category rather than a pure symptomatic cognitive enhancer or a biologic. Note ambiguity: the drug is primarily developed for GI indications clinically, and human AD efficacy is not established \u2014 some sources treat it as a candidate for cognitive/AD research. \ue200cite\ue202turn0search7\ue202turn1search4\ue201."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug velusetrag (TD-5108) is a selective, orally active small\u2011molecule agonist of the serotonin 5\u2011HT4 receptor \u2014 a classical neurotransmitter (serotonin) G\u2011protein coupled receptor. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Trial details and mechanism \u2014 the study is a Phase 1 randomized, placebo\u2011controlled safety/PK/PD trial in healthy elderly subjects testing velusetrag; although 5\u2011HT4 agonists have been shown in preclinical studies to promote non\u2011amyloidogenic APP processing (increase sAPP\u03b1) and reduce A\u03b2 production and to produce pro\u2011cholinergic/cognitive effects, the direct molecular target in humans is the 5\u2011HT4 neurotransmitter receptor. Based on the explicit receptor target, the appropriate CADRO category is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search4\ue202turn1search1\ue202turn1search4\ue201",
        "Reflect: Confirmation and caveats \u2014 classification as D) Neurotransmitter Receptors best matches the drug\u2019s primary pharmacologic target (5\u2011HT4 receptor). While downstream effects on APP/A\u03b2 processing and cognition motivate Alzheimer\u2019s research interest, those are secondary consequences of modulating a neurotransmitter receptor rather than direct targeting of amyloid or tau; therefore D is the most specific CADRO category. If the intent were to classify by downstream pathway (amyloid processing) rather than primary molecular target, A) Amyloid beta could be argued \u2014 but CADRO guidance favors the direct molecular target (the 5\u2011HT4 receptor). \ue200cite\ue202turn1search1\ue202turn1search0\ue201",
        "Web sources used (select): Velusetrag described as a selective 5\u2011HT4 agonist (Theravance press releases/product pages; MedChemExpress). \ue200cite\ue202turn0search0\ue202turn0search1\ue201; Phase 1 / healthy volunteer study and PK/PD GI pharmacology literature. \ue200cite\ue202turn0search4\ue201; Preclinical literature showing 5\u2011HT4 receptor stimulation promotes non\u2011amyloidogenic APP cleavage and can reduce A\u03b2 / improve neuronal survival (PMC and PubMed articles). \ue200cite\ue202turn1search1\ue202turn1search4\ue201"
    ]
}